TIM3 (T-cell immunoglobulin domain and mucindomain-3) is an
activation-induced inhibitory molecule involved in immune tolerance and T-cell
exhaustion in chronic viral infection and cancers. TIM3 maturation
and cell surface expression is facilitated by forming a heterodimeric
interaction with CD66a. Co-blockade of CD66a and TIM3 enhanced anti-tumor immune responses, and
eliminated tumors in mouse colorectal cancer models.
Human TIM3 mAb efficacy evaluation (MC38 cell line)
Fig 1. Murine colon cancer MC38 cells were
subcutaneously implanted into homozygous B-hTIM3 mice. Mice were divided into
control and treatment groups (n = 5) when the tumor volume was about 100 mm3. The anti-human TIM3 antibody
significantly inhibited tumor growth in homozygous B-hTIM3 mice, suggesting
that the B-hTIM3 mouse model is an effective tool for in
antibody efficacy studies. (A) Tumor average volume ± SEM, (B) Mice average
weight ± SEM.